WHY WAIT!
LIVE

Serial Number

79403022

Owner

Clinically Approved Holdings Pty Ltd

Attorney

Amy C. Ziegler

Filing Date

Jun 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

WHY WAIT! Trademark

Serial Number: 79403022 • Registration: 8217231

WHY WAIT! is a trademark filed by Clinically Approved Holdings Pty Ltd on June 12, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 32 (Light Beverages). The application is currently registered and active.

Owner Contact Info

Clinically Approved Holdings Pty Ltd

Ground Fl 36 Esplanade

Entity Type: 82

Trademark Details

Filing Date

June 12, 2024

Registration Date

April 21, 2026

Published for Opposition

March 3, 2026

Goods & Services

Vitamins; mineral supplements; nutritional supplements; multivitamin preparations; pharmaceutical preparations containing vitamins for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical preparations containing omega 3 for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical preparations for metabolic support; pharmaceutical preparations for the improvement of brain health, immunity, sleep, mood, gut health, women's health; pharmaceutical preparations containing vitamins for pregnancy; vitamin supplements; vitamin fortified beverages for medical use; vitamin preparations; medicines for treatment of heart diseases; pharmaceutical products for combating heart diseases; pharmaceutical tablets for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical tablets containing omega 3 for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical tablets for metabolic support; pharmaceutical tablets for the improvement of brain health, immunity, sleep, mood, gut health, women's health; pharmaceutical tablets containing vitamins for pregnancy; anti-inflammatories; vitamin mineral and herbal preparations in tablet and powder form for medical use; dietary nutritional supplements; dietary supplements; dietetic drinks adapted for medical purposes; dietetic food supplements adapted for medical purposes; effervescent vitamin tablets; herbal extracts, other than essential oils, for medical purposes; food supplements, namely, antioxidants, omega 3; dietary food supplements; medicated food supplements; nutritionally fortified beverages adapted for medical purposes; therapeutic agents for weight control and appetite suppression; vitamin tablets; dietary supplements in powder form; medicinal drinks; dietary supplements in capsule form; dietary supplements in liquid capsule form; gummy vitamins; medicines and chemical compounds for the treatment and support of blood circulation; pharmaceutical preparations, medicines and chemical compounds for the treatment of cardiovascular diseases; pharmaceutical preparations, medicines and chemical compounds for the health of blood cells and production of blood lipids, pharmaceutical preparations, medicines and chemical compounds for treatment of cells exposed to oxidants; pharmaceutical preparations, medicines and chemical compounds to treat blood disorders; pharmaceutical preparations, medicines and chemical compounds to treat cardiovascular diseases and for cardiovascular health; chemical preparations for the treatment of cognitive decline; chemical preparations for the treatment of anxiety; chemical preparations for depression; pharmaceutical preparations for the treatment of alzheimers disease; pharmaceutical preparations for the treatment and management of coronavirus disease; pharmaceutical preparations for strengthening human immune responses; pharmaceutical preparations for treatment of influenza variations; pharmaceutical preparations for sleep support; mineral food supplements; analgesics and analgesic preparations; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat blood circulation, artery wellness and strong cardiovascular system, heart disease, healthy red blood cell production and healthy blood lipids, cell energy and to protect cells from oxidative damage and calcium absorption and to maintain healthy blood glucose, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat excessive immune response in relation to coronavirus disease, delivered in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to treat for excessive immune response in humans with influenza, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat Alzheimer's disease, age related mental decline, anxiety and depression, brain fog, stress, ADHD, slow memory and cognitive decline; analgesic preparations, medicines and chemical compounds to improve brain function, brain health during pregnancy and early childhood in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat joint pain, joint disease, arthritis, mild joint aches, and to maintain joint mobility and/or flexibility, healthy joint cartilage growth and/or joint health, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support and assist sleep quality, sleep patterns, and the time required to fall asleep, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to increase calmness, support healthy stress response in the human body, reduce stress and anxiety, relieve symptoms of stress, anxiety or nervous tension, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, and medicines and chemical compounds for the relief and treatment of pain, inflammation, discomfort and swelling in connection with or related to any body component including, without limitation, muscular aches and pains, backache, headache, migraine headache, tension headache, sinus pain, toothache, dental pain, period pain, sore throat, tennis elbow, rheumatic pain, aches and pains associated with colds and flu, female period pain, pain and sleep, pain in connection with manual and/or physical labour, and/or pain in connection with the recovery of injury, harm, decline and damage to any body component, delivered in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds to support and treat eye vision, age-related eye diseases, eye health, eye conditions including dry eye, aged-related Macular Degeneration and/or cataracts, in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds for the treatment of the health and quality of skin, cell growth and renewal, skin damage, skin wrinkle depth, skin hydration, skin appearance, in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds for the treatment of heart health, brain health, eye health, muscle health, joint health, colon, prostate and breast cancers, metabolic syndrome, in liquid, tablet, capsule, powder, tea and gummy form

Non-alcoholic beverages, namely, carbonated beverages; concentrates and powders used in the preparation of soft drinks; drinking water

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 21, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 21, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 3, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 3, 2026 PUBO
NOTIFICATION PROCESSED BY IB
Feb 26, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 25, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 12, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 11, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 10, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 3, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 3, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 3, 2026 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 3, 2026 ERFR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 27, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 27, 2026 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 5, 2025 GNFN
FINAL REFUSAL E-MAILED
Sep 5, 2025 GNFR
FINAL REFUSAL WRITTEN
Sep 5, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 2, 2025 TROA
REFUSAL PROCESSED BY IB
Mar 22, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 4, 2025 RFCS
REFUSAL PROCESSED BY MPU
Mar 4, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 16, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jan 15, 2025 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jan 15, 2025 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 20, 2024 RFCR
NON-FINAL ACTION WRITTEN
Dec 19, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 18, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 30, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 30, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 29, 2024 REPR